Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium

BACKGROUND: Nintedanib (Ofev(®)) and pirfenidone (Esbriet(®)) are recommended by international guidelines as treatment options for idiopathic pulmonary fibrosis (IPF). OBJECTIVES: To compare the cost-effectiveness of nintedanib with that of pirfenidone for the treatment of IPF from a Belgian healthc...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Pharmacoecon Open
Päätekijät: Rinciog, C., Diamantopoulos, A., Gentilini, A., Bondue, B., Dahlqvist, C., Froidure, A., Wuyts, W. A., Soulard, S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer International Publishing 2020
Aiheet:
Original Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7426351/
https://ncbi.nlm.nih.gov/pubmed/31939146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-019-00191-w
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia